JP2018509148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509148A5 JP2018509148A5 JP2017547087A JP2017547087A JP2018509148A5 JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5 JP 2017547087 A JP2017547087 A JP 2017547087A JP 2017547087 A JP2017547087 A JP 2017547087A JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune cells
- cell
- allogeneic
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570138 | 2015-03-11 | ||
| DKPA201570138 | 2015-03-11 | ||
| PCT/EP2016/055332 WO2016142532A1 (en) | 2015-03-11 | 2016-03-11 | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509148A JP2018509148A (ja) | 2018-04-05 |
| JP2018509148A5 true JP2018509148A5 (https=) | 2019-04-11 |
Family
ID=52682595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547087A Pending JP2018509148A (ja) | 2015-03-11 | 2016-03-11 | 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186824B2 (https=) |
| EP (1) | EP3268388A1 (https=) |
| JP (1) | JP2018509148A (https=) |
| KR (1) | KR20170137079A (https=) |
| CN (1) | CN107683333A (https=) |
| AU (1) | AU2016231061B2 (https=) |
| BR (1) | BR112017018224A2 (https=) |
| CA (1) | CA2978840A1 (https=) |
| IL (1) | IL253879A0 (https=) |
| MX (1) | MX2017011418A (https=) |
| RU (1) | RU2017134441A (https=) |
| WO (1) | WO2016142532A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| RU2018106515A (ru) | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| JP2020501512A (ja) * | 2016-09-23 | 2020-01-23 | ユニバーシティ オブ サザン カリフォルニア | キメラ抗原受容体およびその組成物ならびにそれらの使用の方法 |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| WO2018175636A2 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| BR112019021857A2 (pt) * | 2017-04-19 | 2020-06-02 | Allogene Therapeutics, Inc. | Métodos e composições de célula t aperfeiçoada |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| JP7317718B2 (ja) | 2017-06-02 | 2023-07-31 | ファイザー・インク | Ｆｌｔ３を標的にするキメラ抗原受容体 |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| KR20200075851A (ko) * | 2017-10-19 | 2020-06-26 | 셀렉티스 | 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합 |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| WO2019154313A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| US20210077530A1 (en) * | 2018-04-26 | 2021-03-18 | Baylor College Of Medicine | Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cells |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| CN109055380B (zh) * | 2018-09-19 | 2021-08-27 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的制备方法 |
| CA3122131A1 (en) * | 2018-09-21 | 2020-03-26 | Zonghai Li | Method for gene editing of cell on the basis of crispr/cas system |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| AU2020221324A1 (en) | 2019-02-15 | 2021-09-02 | University Of Southern California | Lym-1 and Lym-2 antibody compositions and improved CAR constructs |
| CA3130698A1 (en) * | 2019-03-18 | 2020-09-24 | Steven John GRECO | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
| US12006511B2 (en) | 2019-04-15 | 2024-06-11 | The Medical College Of Wisconsin, Inc. | Recombinant PD-L1 peptides and methods of use |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020231882A2 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| EP3991746A4 (en) * | 2019-06-26 | 2023-08-09 | Takeda Pharmaceutical Company Limited | TRANSFECTION METHOD |
| WO2021022044A1 (en) * | 2019-07-31 | 2021-02-04 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| EP4073103A1 (en) | 2019-12-11 | 2022-10-19 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| KR102246067B1 (ko) * | 2020-05-13 | 2021-04-29 | (주)세렌라이프 | 효능이 증진된 줄기세포를 포함하는 세포 생착능 증진용 조성물 |
| EP4159846A4 (en) * | 2020-05-26 | 2024-08-14 | Healios K.K. | HYPOIMMUNOGENIC CELLS |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| KR102859550B1 (ko) | 2020-08-20 | 2025-09-16 | 에이투 바이오쎄라퓨틱스, 인크. | Ceacam 양성 암을 치료하기 위한 조성물 및 방법 |
| AU2021328478A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022115472A1 (en) * | 2020-11-24 | 2022-06-02 | A2 Biotherapeutics, Inc. | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| WO2022192895A1 (en) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20060222633A1 (en) | 2000-05-11 | 2006-10-05 | Yale University | Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US9982251B2 (en) | 2003-03-14 | 2018-05-29 | Cellectis S.A. | Large volume ex vivo electroporation method |
| KR100912994B1 (ko) | 2004-04-05 | 2009-08-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Ｎｋｇ２ｄ의 조절 |
| US8986712B2 (en) | 2009-11-29 | 2015-03-24 | Yeda Research And Development Co., Ltd. | Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| MX2015015638A (es) * | 2013-05-13 | 2016-10-28 | Cellectis | Metodos para diseñar celulas t altamente activas para inmunoterapia. |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2943008C (en) | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
-
2016
- 2016-03-11 KR KR1020177028154A patent/KR20170137079A/ko not_active Withdrawn
- 2016-03-11 WO PCT/EP2016/055332 patent/WO2016142532A1/en not_active Ceased
- 2016-03-11 MX MX2017011418A patent/MX2017011418A/es unknown
- 2016-03-11 US US15/556,558 patent/US11186824B2/en active Active
- 2016-03-11 CA CA2978840A patent/CA2978840A1/en active Pending
- 2016-03-11 CN CN201680014457.5A patent/CN107683333A/zh active Pending
- 2016-03-11 AU AU2016231061A patent/AU2016231061B2/en active Active
- 2016-03-11 EP EP16710948.7A patent/EP3268388A1/en active Pending
- 2016-03-11 JP JP2017547087A patent/JP2018509148A/ja active Pending
- 2016-03-11 BR BR112017018224-6A patent/BR112017018224A2/en not_active IP Right Cessation
- 2016-03-11 RU RU2017134441A patent/RU2017134441A/ru not_active Application Discontinuation
-
2017
- 2017-08-07 IL IL253879A patent/IL253879A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509148A5 (https=) | ||
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| RU2017134441A (ru) | Способы конструирования аллогенных т-клеток для повышения их персистенции и/или приживления у пациентов | |
| Miliotou et al. | CAR T-cell therapy: a new era in cancer immunotherapy | |
| Vella et al. | CD4+ T cell differentiation in chronic viral infections: the Tfh perspective | |
| Gargett et al. | GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade | |
| JP2019528769A5 (https=) | ||
| Escobar et al. | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2017535284A5 (https=) | ||
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| Boettcher et al. | Development of CAR T cell therapy in children—A comprehensive overview | |
| JP2019531745A5 (https=) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| WO2013176916A8 (en) | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells | |
| JP2018529327A5 (https=) | ||
| WO2019232409A9 (en) | Methods for genome editing and activation of cells | |
| PH12020551124A1 (en) | Bispecific antibody | |
| CA2924252C (en) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2018509163A5 (https=) | ||
| JP2015143226A5 (https=) | ||
| MX2023004169A (es) | Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas. | |
| JP2017513472A5 (https=) | ||
| JP2019507180A5 (https=) |